计算机断层扫描冠状动脉扫描与计算机断层扫描在现实世界人口中的断片流量储备的积极预测值
Hannah Sinclair1,2, Reuben Loi Yongli1,3, Mohamed Farag1
1Cardiothoracic Department, Freeman Hospital, Newcastle Upon Tyne, Gateshead, UK.
概括
计算机断层扫描冠状动脉扫描 (CTCA) 和CT-FFR在现实世界具有较低的积极预测值. 然而,CT-FFR对稳定的心痛可靠,对非典型症状优越,可能减少不必要的侵入性手术.
科学领域:
- 心脏病学 心脏病学
- 医疗成像医学成像
- 诊断工具 诊断工具
背景情况:
- 计算机断层扫描冠状动脉扫描 (CTCA) 和CT-FFR是检测流量限制冠状动脉狭窄的非侵入性工具.
- 有关这些测试的高灵敏度存在担忧,可能导致冠状动脉疾病 (CAD) 的过度诊断和不必要的侵入性冠状动脉血管学 (ICA).
- 这项研究旨在比较CT-FFR和CTCA与ICA在各种现实患者队列中的积极预测值 (PPV).
研究的目的:
- 评估CT-FFR和CTCA在诊断冠状动脉疾病 (CAD) 中的现实世界的正预测值 (PPV).
- 为了比较CT-FFR和CTCA在不同患者组和测试指示的诊断性能.
- 评估CT-FFR在潜在减少不必要的侵入性冠状动脉血管学 (ICA) 中的实用性.
主要方法:
- 对477名因怀疑冠状动脉缺血而接受CTCA或CT-FFR的患者进行了回顾性分析.
- 对CTCA和CT-FFR进行基于患者的PPV计算,显著的CAD定义为ICA上>70%的狭窄.
- 基于扫描的指示和与侵入性压力线测量进行比较的PPV子分析.
主要成果:
- 总体PPV为CTCA的59.3%,CT-FFR的76.2%.
- 对于患有稳定性胸痛的患者,PPV增加到CTCA的81.0%,CT-FFR的86.7%.
- CT-FFR显示,与CTCA (37.5%) 相比,在非典型心痛症状的患者中,PPV (61.3%) 更高. 在侵入式压力线测量和CT-FFR (r=0.23,P=0.265) 之间没有发现显著的线性相关性.
结论:
- 在现实世界中,CTCA和CT-FFR的PPV比以前报告的要低,受患者选择和扫描指示的影响.
- 无论是CTCA还是CT-FFR,都可靠地诊断出典型心痛症状的患者的显著冠状动脉狭窄症.
- CT-FFR在非典型心痛病例中表现出卓越的性能,这表明其有针对性的使用可以最大限度地减少不必要的侵入性手术.
相关概念视频
Imaging Studies for Cardiovascular System V: CT
Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...


